Correction: Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)

Résumé fourni par la source

In the sentence beginning 'Efficacy outcomes for participants entering ADjoin from…….' in this article under "Statistical Analyses", the line starting with "Participants who received systemic or topical rescue medication or discontinued treatment for any other reasons had values set to missing subsequent to this time through to ADjoin week 100 and MI was used to handle the missing data."should have read "Participants who discontinued treatment for any other reasons had values set to missing subsequent to this time through to ADjoin week 100 and MI was used to handle the missing data."

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.